ArticleExperimental & molecular medicine2026
COL1A1-induced LOXL2 promotes ovarian cancer metastasis via a feedback loop upon inhibiting EGFR lysosomal degradation.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ATF3/SOX11-regulated FST activates IGF1R-ERK/AKT-Sp1 signaling to sustain trigeminal neuropathic pain.Acta pharmacologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Widespread peritoneal metastasis is a key reason for high mortality in ovarian cancer and understanding its mechanisms will offer new targets for the effective treatment of metastatic ovarian cancer. Our previous research revealed that collagen type I alpha 1 (COL1A1)-induced upregulation of lysyl oxidase-like 2 (LOXL2) was markedly overexpressed in ovarian cancer tissue samples and ascites. LOXL2 serves as an independent risk factor for predicting prognosis and its high expression is associated with high-risk clinical factors. LOXL2 promoted migration and invasion of ovarian cancer cells and metastasis of transplanted tumors in the xenograft mouse model. Here we determined that, mechanistically, COL1A1 activated the EGFR-MEK-ERK signaling pathway, which subsequently facilitated the nuclear translocation of SP1. SP1 binds to the promoter region of LOXL2, augmenting its transcription. Meanwhile, LOXL2 interacts with EGFR, protecting it from lysosomal degradation and enhancing protein stability. Finally, EGFR activates the MEK-ERK signaling pathway, promoting the translocation of SP1 and forming positive feedback. Our findings confirmed the molecular mechanism by which COL1A1-induced upregulation of LOXL2 promotes ovarian cancer metastasis through a positive feedback loop involving EGFR-MEK-ERK-SP1, offering novel scientific insights and potential therapeutic targets for inhibiting ovarian cancer metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.